.: ORİJİNAL ARAŞTIRMA
Hereditary Thrombophilia Profile and Clinical Results of Our Eastern Black Sea Region Pulmonary Embolism Patients: Descriptive Research
Doğu Karadeniz Bölgesi Pulmoner Emboli Hastalarımızın Herediter Trombofili Profili ve Klinik Sonuçları: Tanımlayıcı Araştırma
Turkiye Klinikleri J Intern Med. 2023;8(2):50-7
doi: 10.5336/intermed.2023-95575
Makale Dili: EN
Tam Metin
ABSTRACT
Objective: The frequency and clinical implications of mutations causing hereditary thrombophilia are unclear. We aimed to investigate the frequency and clinical implications of gene mutations causing hereditary thrombophilia in patients with pulmonary embolism. Materials and Methods: The study included patients with pulmonary embolism who were investigated for hereditary thrombophilia. Data were collected retrospectively. Results: 107 (3.2%) of 3,340 patients with pulmonary embolism were found to have hereditary thrombophilia. Of the patients, 54 (50.5%) were female and 53 (49.5%) were male. MTHFR 677 was found in 37 (19.8%), factor V Leiden in 34 (18.2%), MTHFR1298 in 31 (16.6%), prothrombin 20210 in 13 (7.0%), AFAS in 12 (6.4%), AT III deficiency was present in 4 (2.1%), protein C resistance in 1 (0.5%), protein C deficiency in 1 (0.5%), and protein S deficiency in 1 (0.5%). The most common mutation was MTHFR 677 (22-33%) in women and factor V Leiden (22-32%) in men. MTHFR 677 was the most frequently observed mutation regardless of gender. The coexistence of pulmonary embolism and deep vein thrombosis (DVT) (34%), presence of acute DVT (31.3%), concomitant arterial thrombosis (30.6%), and recurrence of pulmonary embolism (25.6%) were higher in factor V Leiden deficiency than in other mutations. The highest heterozygosity rate was found in factor V Leiden. Conclusion: In our study, hereditary thrombophilia was detected in 3.2% of the pulmonary embolism patient population. The most common genetic mutations in our region are MTHFR 677 and factor V Leiden.
Keywords: Thrombophilia; pulmonary embolism; thrombosis
Objective: The frequency and clinical implications of mutations causing hereditary thrombophilia are unclear. We aimed to investigate the frequency and clinical implications of gene mutations causing hereditary thrombophilia in patients with pulmonary embolism. Materials and Methods: The study included patients with pulmonary embolism who were investigated for hereditary thrombophilia. Data were collected retrospectively. Results: 107 (3.2%) of 3,340 patients with pulmonary embolism were found to have hereditary thrombophilia. Of the patients, 54 (50.5%) were female and 53 (49.5%) were male. MTHFR 677 was found in 37 (19.8%), factor V Leiden in 34 (18.2%), MTHFR1298 in 31 (16.6%), prothrombin 20210 in 13 (7.0%), AFAS in 12 (6.4%), AT III deficiency was present in 4 (2.1%), protein C resistance in 1 (0.5%), protein C deficiency in 1 (0.5%), and protein S deficiency in 1 (0.5%). The most common mutation was MTHFR 677 (22-33%) in women and factor V Leiden (22-32%) in men. MTHFR 677 was the most frequently observed mutation regardless of gender. The coexistence of pulmonary embolism and deep vein thrombosis (DVT) (34%), presence of acute DVT (31.3%), concomitant arterial thrombosis (30.6%), and recurrence of pulmonary embolism (25.6%) were higher in factor V Leiden deficiency than in other mutations. The highest heterozygosity rate was found in factor V Leiden. Conclusion: In our study, hereditary thrombophilia was detected in 3.2% of the pulmonary embolism patient population. The most common genetic mutations in our region are MTHFR 677 and factor V Leiden.
Keywords: Thrombophilia; pulmonary embolism; thrombosis
ÖZET
Amaç: Herediter trombofiliye nedeni mutasyonların sıklığı ve klinik yansımaları net değildir. Pulmoner embolili hastalarda herediter trombofiliye neden olan gen mutasyonlarının sıklığı ve klinik yansımalarının araştırılması amaçlanmıştır. Gereç ve Yöntemler: Çalışmaya, herediter trombofili araştırılan pulmoner embolili hastalar dâhil edildi. Veriler retrospektif toplandı. Bulgular: 3.340 pulmoner embolili hastasının 107'sinde (%3,2) herediter trombofili saptandı. Hastaların 54'ü (%50,5) kadın, 53'ü (%49,5) erkekti. Hastaların 37'sinde (%19,8) MTHFR 677, 34'ünde (%18,2) faktör V Leiden, 31'inde (%16,6) MTHFR1298, 13'ünde (%7,0) protrombin 20210, 12'sinde (%6,4) AFAS, 4'ünde (%2,1) AT III eksikliği, 1'inde (%0,5) protein C rezistansı, 1'inde (%0,5) protein C eksikliği, 1'inde (%0,5) protein S eksikliği mevcuttu. Kadınlarda en sık gözlenen mutasyon MTHFR 677 (%22-33), erkeklerde faktör V Leiden (%22-32) idi. MTHFR 677 cinsiyet ayrımı yapılmaksızın en sık gözlenen mutasyondu. Faktör V Leiden eksikliğinde, pulmoner emboli ve derin ven trombozu (DVT) birlikteliğinin (%34), akut DVT varlığının (%31,3), eşlik eden arteriyel trombozun (%30,6), pulmoner emboli nüksünün (%25,6) diğer mutasyonlardan daha yüksek olduğu gözlendi. En yüksek heterozigotluk oranı faktör V Leiden'de bulundu. Sonuç: Çalışmamız ile pulmoner emboli hasta popülasyonununda herediter trombofili %3,2 oranında saptanmıştır. Bölgemizde en sık rastlanan genetik mutasyonlar MTHFR 677 ve faktör V Leiden'dir.
Anahtar Kelimeler: Trombofili; pulmoner emboli; tromboz
Amaç: Herediter trombofiliye nedeni mutasyonların sıklığı ve klinik yansımaları net değildir. Pulmoner embolili hastalarda herediter trombofiliye neden olan gen mutasyonlarının sıklığı ve klinik yansımalarının araştırılması amaçlanmıştır. Gereç ve Yöntemler: Çalışmaya, herediter trombofili araştırılan pulmoner embolili hastalar dâhil edildi. Veriler retrospektif toplandı. Bulgular: 3.340 pulmoner embolili hastasının 107'sinde (%3,2) herediter trombofili saptandı. Hastaların 54'ü (%50,5) kadın, 53'ü (%49,5) erkekti. Hastaların 37'sinde (%19,8) MTHFR 677, 34'ünde (%18,2) faktör V Leiden, 31'inde (%16,6) MTHFR1298, 13'ünde (%7,0) protrombin 20210, 12'sinde (%6,4) AFAS, 4'ünde (%2,1) AT III eksikliği, 1'inde (%0,5) protein C rezistansı, 1'inde (%0,5) protein C eksikliği, 1'inde (%0,5) protein S eksikliği mevcuttu. Kadınlarda en sık gözlenen mutasyon MTHFR 677 (%22-33), erkeklerde faktör V Leiden (%22-32) idi. MTHFR 677 cinsiyet ayrımı yapılmaksızın en sık gözlenen mutasyondu. Faktör V Leiden eksikliğinde, pulmoner emboli ve derin ven trombozu (DVT) birlikteliğinin (%34), akut DVT varlığının (%31,3), eşlik eden arteriyel trombozun (%30,6), pulmoner emboli nüksünün (%25,6) diğer mutasyonlardan daha yüksek olduğu gözlendi. En yüksek heterozigotluk oranı faktör V Leiden'de bulundu. Sonuç: Çalışmamız ile pulmoner emboli hasta popülasyonununda herediter trombofili %3,2 oranında saptanmıştır. Bölgemizde en sık rastlanan genetik mutasyonlar MTHFR 677 ve faktör V Leiden'dir.
Anahtar Kelimeler: Trombofili; pulmoner emboli; tromboz
REFERANSLAR:
- Khan F, Tritschler T, Kahn SR, Rodger MA. Venous thromboembolism. Lancet. 2021;398(10294):64-77. [Crossref] [PubMed]
- Şentürk A. Herediter trombofili [Hereditary thrombophilia]. Güncel Göğüs Hastalıkları Serisi. 2015;3(1):16-23. [Link]
- Foy P, Moll S. Thrombophilia: 2009 update. Curr Treat Options Cardiovasc Med. 2009;11(2):114-28. [Crossref] [PubMed]
- Oguzulgen IK, Yilmaz E, Demirtas S, Erkekol FO, Ekim N, Demir N, et al. The role of plasminogen activator inhibitor-1 polymorphism, factor-V-Leiden, and prothrombin-20210 mutations in pulmonary thromboembolism. Clin Appl Thromb Hemost. 2009;15(1):73-7. Erratum in: Clin Appl Thromb Hemost. 2009;15(3):367. Yilmaz, E [added]. [Crossref] [PubMed]
- Atahan E, Çağlar E, Şarkış C, Uğurlu S. Venöz tromboemboli ve kalıtsal trombofili [Venous thromboembolism and inherited thrombophilia]. Turkish J Thorac Cardiovasc Surg. 2009;17(4):302-11. [Link]
- Stern RM, Al-Samkari H, Connors JM. Thrombophilia evaluation in pulmonary embolism. Curr Opin Cardiol. 2019;34(6):603-9. [Crossref] [PubMed]
- Gurgey A, Haznedaroglu IC, Egesel T, Buyukasik Y, Ozcebe OI, Sayinalp N, et al. Two common genetic thrombotic risk factors: factor V Leiden and prothrombin G20210A in adult Turkish patients with thrombosis. Am J Hematol. 2001;67(2):107-11. [Crossref] [PubMed]
- Demir M, Vural O, Sunar H, Altun A, Yorulmaz F, Ozbay G. The prevalence of hereditary thrombophilia in the Trakya region of Turkey. Yonsei Med J. 2000;41(4):436-40. [Crossref] [PubMed]
- Oguzulgen IK, Ekim NN, Akar N, Demirel K, Kitapci M. The role of thrombophilic risk factors in the severity of pulmonary thromboembolism. Eur Respir J. 2002;19(4):709-11. [Crossref] [PubMed]
- Martinelli I, Mannucci PM, De Stefano V, Taioli E, Rossi V, Crosti F, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood. 1998;92(7):2353-8. [Crossref] [PubMed]
- Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. J Thromb Haemost. 2009;7 Suppl 1:301-4. [Crossref] [PubMed]
- Simone B, De Stefano V, Leoncini E, Zacho J, Martinelli I, Emmerich J, et al. Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol. 2013;28(8):621-47. [Crossref] [PubMed] [PMC]
- Türk Toraks Dernerği. Pulmoner Tromboembolizm Tanı ve Tedavi Uzlaşı Raporu 2021. Optimus Yayıncılık; 2021. [Link]
- Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA. 1997;277(16):1305-7. [Crossref] [PubMed]
- Mitrus JM, Wierszyło E. Prevalence of the factor V leiden mutation in patients susceptible to venous thromboembolism. Health Prob Civil. 2020;14(2):2. [Crossref]
- Nefic H, Mackic-Djurovic M, Eminovic I. The Frequency of the 677C>T and 1298A>C Polymorphisms in the Methylenetetrahydrofolate Reductase (MTHFR) Gene in the Population. Med Arch. 2018;72(3):164-9. [Crossref] [PubMed] [PMC]
- Colvin BT. Recent advances in blood coagulation. Hematologycal Oncology. 1985;4(2):117-30. [Crossref]
- Kalkanli S, Ayyildiz O, Tiftik N, Batun S. Factor V Leiden mutation in our region. XIX. National Gevher Nesibe Meeting. Congress and Workshop of Hematology-Oncology, Congress Book (Turkish). Nevşehir, Türkiye, May 24-26, 2001. p.106.
- Okumus G, Kiyan E, Arseven O, Tabak L, Diz-Kucukkaya R, Unlucerci Y, et al. Hereditary thrombophilic risk factors and venous thromboembolism in Istanbul, Turkey: the role in different clinical manifestations of venous thromboembolism. Clin Appl Thromb Hemost. 2008;14(2):168-73. [Crossref] [PubMed]
- van Vlijmen EF, Wiewel-Verschueren S, Monster TB, Meijer K. Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2016;14(7):1393-403. [Crossref] [PubMed]
- Bilici M, Öz İİ, İlikhan SU, Arslaner M, Kahraman E, Kılavuz B, et al. The predictive value of factor V Leiden, prothrombin G20210A and MTHFR C677T Gene mutations on the location of venous thromboembolism. Dicle Medical Journal. 2015;42(4):467-71. [Link]
- Suchon P, Resseguier N, Ibrahim M, Robin A, Venton G, Barthet MC, et al. Common risk factors add to inherited thrombophilia to predict venous thromboembolism risk in families. TH Open. 2019;3(1):e28-e35. [Crossref] [PubMed] [PMC]
- Obaid M, El-Menyar A, Asim M, Al-Thani H. Prevalence and outcomes of thrombophilia in patients with acute pulmonary embolism. Vasc Health Risk Manag. 2020;16:75-85. [Crossref] [PubMed] [PMC]
- Martinelli I, Battaglioli T, Razzari C, Mannucci PM. Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia. J Thromb Haemost. 2007;5(1):98-101. [Crossref] [PubMed]
- Bombeli T, Basic A, Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol. 2002;70(2):126-32. [Crossref] [PubMed]
.: İşlem Listesi